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ABSTRACT
Background: The study investigated the economic burden of vaso-occlusive crisis (VOC) among 
sickle cell disease (SCD) patients, through assessment of overall utilization and costs and costs per 
VOC episode (regarding the number of VOC episodes and health care setting, respectively).
Methods: Using the Medicaid Analytic Extracts database, the first SCD-related diagnosis claim (index 
claim) between June 1, 2009–December 31, 2012 was identified among eligible adults. Patients were 
required to have continuous medical and pharmacy benefits for 6 months pre- and 12 months post-
index. Discrete VOC claims identified within a 3-day gap were combined as a single VOC episode. 
Annual all-cause and SCD-related medical resources and costs were identified and stratified by number 
of VOC episodes during the 1-year follow-up period. Health care costs per VOC episode were also 
examined, stratified by care setting.
Results: Enrollees included 8521 eligible patients with a mean age of 32.88 years (SD=12.21). Of 
these, 66.5% had a Charlson Comorbidity index (CCI) score of 0 (no comorbidities) and 67.3% 
were female. The average total medical costs were US$34 136 (median=US$12 691) annually, and 
SCD accounted for 60% of the total costs (mean=US$20 206, median=US$1204). Patients with >3 
episodes had the highest annual SCD-related costs (mean=US$58 950) across all settings. Health 
care resource utilization (HCRU) and costs increased substantially as the number of VOC episodes 
increased. This study was limited to observation of associations rather than causal inference, and by 
possible coding and identification discrepancies and the restricted generalizability of the population. 
Conclusions: VOC has a severe impact on medical resource use and costs among the adult SCD 
population. Further research among broader study populations is needed to facilitate the reduction of 
VOC episodes and thereby improve clinical and economic outcomes for SCD patients. 
INTRODUCTION
Sickle cell disease (SCD) is a complex genetic blood disease in which 
erythrocytes have the propensity to change into a crescent (sickle) shape. 
This increases interactions with other endovascular cells and causes 
endothelium dysfunction, inflammation, and vascular damage.1,2 Of 
note, multi-cell adhesion between red blood cells, white blood cells, 
platelets, and endothelial cells can result in painful vaso-occlusion.3–5
Vaso-occlusive crisis (VOC) is the hallmark of SCD and sometimes 
the precursor to many life-threatening complications such as acute 
chest syndrome (ACS), stroke, splenic sequestration, and multisystem 
organ failure.6,7 Although VOC is painful and often requires immediate 
medical intervention such as emergency care and hospitalization, 
studies have shown that VOC episodes are also sometimes managed at 
home without emergency department (ER) visits or hospitalization.8,9 
As VOCs significantly impact SCD patients’ quality of life (QOL), it is 
important for clinicians to minimize their number.
In addition to its serious impact on QOL, SCD and its 
complications incur a significant economic burden. It is estimated 
that in 2005, the mean annual expenditure for children with SCD was 
US$11 702 under Medicaid coverage and US$14 772 under employer-
sponsored insurance.10 In particular, SCD-related health care costs
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for adults rise because many are forced to rely on urgent care, as their 
access to preventive and comprehensive health care is limited by a lack 
of providers and reduced insurance coverage.11 In one study on costs 
between 2001–2005, the per patient-month total health care costs of 
patients aged 50–64 years averaged US$2562—three times that of a 
group aged 0–9 years.12
SCD management is complicated as well as costly, in part due to 
the many dimensions of care. For instance, prevention of infectious 
diseases and SCD-related complications is necessary from early 
childhood. Such preventive approaches include newborn screening, 
anti-infection vaccinations, and the use of antibiotics from birth 
until completion of the initial series of vaccinations for encapsulated 
organisms. Also, to preempt the onset of neurologic complications, 
annual transcranial doppler ultrasonography screening is used to 
monitor stroke risk and assess the need for prophylactic transfusion 
therapy to prevent primary strokes.13
Among SCD maintenance treatments, blood marrow transplant 
(BMT), the amino acid L-glutamine (Endari™), voxelotor, and 
crizanlizumab-tmca have recently been added to the established use 
of blood transfusion and hydroxyurea (HU). HU has been shown to 
reduce the incidence of VOC and ACS as well as decrease necessary 
blood cell transfusions and overall health care resource utilization 
(HCRU); nonetheless, it remains underutilized.14-18
Because of these high levels of service and resource requirements, 
one of the main challenges of SCD management is HCRU, which is 
driven primarily by costly ER visits and hospitalizations.19 As its onset is 
often sudden and severe, VOC routinely requires urgent interventions 
(such as hospital admissions and emergency care) to prevent further 
life-threatening complications.13,20 Together with its contribution to 
morbidity and mortality, VOC’s substantial elevation of HCRU and 
costs has made VOC management an emphasis of SCD treatment 
patterns.21
As there is limited evidence on the economic burden of SCD, 
especially for adult patients, the purpose of this study was to provide a 
comprehensive breakdown of adult SCD patient direct medical costs, 
including all-cause and SCD-related HCRU and costs. Specifically, we 
stratified total costs (by the number of VOC episodes) and costs per 
VOC episode (by care setting) to provide a detailed examination of 
the association between VOC frequency and SCD economic burden.
METHODS
Study Design
This was a retrospective cohort analysis of patient-level data extracted 
from the United States Medicaid MAX databases from January 1, 2009 
through December 31, 2013. The most recent 5 years of data were used 
at the time of the study and data was accessed through the Centers for 
Medicare and Medicaid Services (CMS). 
The study included fee-for-service (FFS) patients from all available 
states and Managed Care enrollees who resided in the following 14 states 
with complete data: Arizona, California, Indiana, Kansas, Kentucky, 
Minnesota, Nebraska, New Jersey, New Mexico, New York, Oregon, 
Tennessee, Texas, and Virginia (managed care information for patients 
residing elsewhere was incomplete in the CMS MAX database).22
Patient Selection
Patients were included in the study if they were aged ≥18 years and 
had an SCD diagnosis in any position (ICD-9-CM codes 282.41, 
282.42, 282.60-282.69) during the identification period (July 1, 
2009–December 31, 2012). The date of the first observed SCD-related 
diagnosis during the identification period was designated as the index 
date. Patients were required to have continuous enrollment with 
medical and pharmacy coverage for the 6-month baseline and ≥1 year 
of follow-up after the index date, and were followed until the earliest 
of disenrollment, death, or end of study. Patients who were enrolled 
in a clinical trial during the study period were excluded due to unique 
treatment patterns that could influence study outcomes.
Patients with VOC episodes were identified at any time after the 
index date using ICD-9-CM codes (282.42, 282.62, 282.64, 282.69). 
Because treatments for 1 VOC episode can be administered in multiple 
settings within a given time window, discrete VOC claims within a 
3-day gap were combined and recorded as a single VOC episode. 
OUTCOME ASSESSMENTS
HCRU and Costs For 1 Year
Annual all-cause and SCD-related HCRU and costs for each patient 
were evaluated during the 12 months after the index date. For HCRU 
analysis, the length of inpatient stays and the number of visits were 
computed for the fixed 1-year period (including inpatient, outpatient, 
ER, outpatient hospital, ambulatory surgery center, lab, hospice, long-
term care [LTC], and pharmacy department visits).
For analysis of health care costs by facility type, only FFS patients 
were calculated (Managed Care cost data are unavailable in the CMS 
MAX database). Costs were adjusted to 2013 US dollars using the 
medical care component of the Consumer Price Index (CPI). 
HCRU and costs were considered SCD-related if they were 
associated with an SCD diagnosis, SCD medications (eg, opioids, 
nonsteroidal anti-inflammatory drugs [NSAIDs], and hydroxyurea), 
or other SCD management procedures (eg, blood transfusion). 
SCD-related HCRU and costs were also stratified by number of 
VOC episodes in the 1-year follow-up period. Patients were separated 
into four cohorts, according to number of VOC episodes (0, 1, 2, and 
≥3). 
Costs Per VOC Episode
Costs per VOC episode were identified in any setting and classified by 
place of service using a hierarchical order: inpatient, ER, outpatient, 
office, and other. The definition of outpatient VOCs included 
those in the outpatient hospital, ambulatory surgery center, nursing 
facility, or long-term care settings. Office VOCs included those in 
the independent clinic, federally qualified health center, state or local 
public health clinic, or rural health clinic settings.
Health care costs during the VOC episodes were identified and 
included the total medical costs in any setting and outpatient pharmacy 
costs related to SCD treatments. Average costs per VOC episode were 
calculated for all VOC episodes and for each setting of care. 
Statistical Analyses
Numbers and percentages are reported for categorical variables. Mean 
values and standard deviations are reported for continuous variables. 
RESULTS
Patient Baseline Characteristics
This analysis included 8521 qualifying adult patients with SCD (Figure 
1), most of whom were relatively young African American women with 
no comorbidities. The mean age of patients was 32.9 years (SD=12.2) 
and more than half (51.9%) were in the 18–30 year age group. Nearly 
three-quarters (74%) were African American, followed by Hispanic 
(10.1%) and unknown race (6.8%). Females accounted for 67.3% of 
the patients and 66.5% had a CCI score of 0. (Table 1) 
Among all eligible patients, 24.6% had ≥1 VOC requiring an 
inpatient stay during the 6-month baseline period. Infectious disease 
(19.74%) was the most common baseline comorbidity, followed by 
asthma (10.9%), fever (9.3%), and neoplasms (7.2%). (Table 2)
For baseline SCD management, 44.8% of the patients were 
prescribed antibiotics, followed by acetaminophen (44.1%), folic 
acid (29.8%), opioids (28.1%), and NSAIDs (26%); 10.8% used 
hydroxyurea, and 14% had a blood transfusion. Assessment of baseline 
all-cause HCRU found 53.6% of the patients had ≥1 outpatient ER 
visit and 29.8% had ≥1 inpatient visit. (Table 2)
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Figure 1. Patient Selection
ID: identification; SCD: sickle cell disease
Table 1. Patient Demographic Characteristics
Sickle Cell Patients* (Age ≥18) 
(N = 8521)
Baseline Demographics N/Mean %/SD
Age (Years) 32.88 12.21


















North Central 843 9.9%
* The following ICD-9-CM codes 282.41, 282.42, 282.60-282.69 were used to identify SCD patients.
Abbreviations: N, number; SD, standard deviation.
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Table 2. Baseline Clinical Characteristics and Utilization
 
Sickle Cell Patients (Age ≥18)
(N = 8521)
Baseline Clinical Characteristics N/Mean %/SD





Patients With Baseline VOC Episodes 2097 24.6%
Baseline Number of VOC Episodes (6 months) 1.04 2.72
Individual Comorbid Conditions*
Neoplasms benign and malignant 617 7.2%
Seizures 393 4.6%
Asthma 928 10.9%
Upper respiratory tract infections 565 6.6%
Acute chest syndrome 233 2.7%
Infectious and parasitic diseases 1682 19.7%
Fever 792 9.3%
Constipation 501 5.9%
Chronic pain 418 4.9%
Iron overload 367 4.3%
Aseptic (avascular) bone necrosis 359 4.2%
Baseline SCD Management
SCD Medication*    
Antibiotics 3819 44.8%
Acetaminophen 3756 44.1%
Folic acid 2542 29.8%
Opioids (narcotics) 2393 28.1%
NSAIDs 2214 26.0%
Hydroxyurea 921 10.8%
Other SCD Management*    
Blood transfusions 1189 14.0%
Baseline All-Cause Health Care Resource*    
Any pharmacy visit 7266 85.3%
Any outpatient hospital visit 5992 70.3%
Any outpatient office visit 5923 69.5%
Any outpatient ER visit 4563 53.6%
Any outpatient other visit 3580 42.0%
Any lab visit 3318 38.9%
Any inpatient stay 2543 29.8%
* Only individual comorbidities with ≥4% are reported.
Abbreviations: ER, Emergency room; N, number; NSAIDs, nonsteroidal anti-inflammatory drugs; 
PDE-5, phosphodiesterase type 5; SD, standard deviation; VOC, vaso-occlusive crisis.
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Table 3. Annual All-Cause and SCD-Related HCRU and Costs
Follow-Up All-Cause HCRU and Costs in the First 12 Months 
Facility Type % Patients With ≥1 Visit Mean Costs Median of Costs 
Inpatient 56.3% US$17 535 US$1590
Outpatient other 56.0% US$6891 US$0
Pharmacy 95.2% US$3898 US$0
Long-term care (LTC) 3.0% US$2665 US$169
Outpatient hospital 87.4% US$2081 US$0
Outpatient ER 73.3% US$592 US$0
Outpatient office 83.6% US$397 US$0
Hospice 0.1% US$34 US$3577
Lab 55.5% US$33 US$0
Ambulatory surgery center 4.5% US$12 US$281
Total (inpatient + outpatient + LTC + pharmacy) Cost US$34 136 US$12 691
Follow-Up SCD-Related HCRU and Costs in the First 12 Months 
Facility Type % Patients with ≥1 visit Mean Costs Median of Costs
Inpatient 42.7% US$15 237 US$0
Pharmacy 82.0% US$2584 US$0
Outpatient hospital 65.2% US$723 US$0
Outpatient other 28.7% US$685 US$0
Long-term Care (LTC) 1.2% US$498 US$0
Outpatient ER 49.9% US$402 US$0
Outpatient office 47.7% US$64 US$0
Lab 27.1% US$8 US$0
Ambulatory surgery center 1.7% US$5 US$0
Hospice 0.0% US$0 US$0
Total (inpatient + outpatient + LTC + pharmacy) Cost US$20 206 US$1204
Note: Health care costs were examined among patients with FFS Medicaid plan. 
Abbreviations: LTC, long-term care; SCD, sickle cell disease; HCRU, health care resource utilization; FFS, fee-for-service; ER, emergency department
Annual All-Cause and SCD-Related HCRU and Costs During the 
Post-index Period
Among the 8521 total adult patients with SCD, 49.8% (N = 4247) 
had an FFS Medicaid plan and were included in the analysis for 
health care costs. The average total medical costs were US$34 136 
(median=US$12 691) in 1 year and SCD accounted for 60% of the 
total costs (mean=US$20 206, median=US$1204). The largest all-
cause medical cost driver was inpatient costs, with average annual 
expenditure at US$17 535 (median=US$1590) per patient; SCD 
accounted for around 87% of these inpatient costs (mean=US$15 237). 
SCD also contributed to high proportions of costs in other settings 
such as pharmacy (67%) and ER (68%). 
The study population also utilized health care resources 
frequently. Almost all the enrolled patients had ≥1 all-cause pharmacy 
visit (95.2%), and 86% of these visits were related to SCD treatments. 
Large proportions of the patients had ≥1 all-cause outpatient hospital 
(87.4%) and outpatient office visit (83.6%), with 57% and 75% of 
these visits due to SCD, respectively. (Table 3)
SCD-Related Costs and HCRU Stratified by Number of VOC 
Episodes 
Among the 8521 enrollees, most had no VOC episode during the 1-year 
follow-up period, but a large number had ≥3 episodes. Specifically, 
4452 patients had no episode, 1253 had 1 episode, 570 had 2 episodes, 
and 2246 had ≥3 episodes. 
Regarding SCD-related HCRU, patients with ≥3 episodes had 
the highest mean number of outpatient hospital visits (mean=33.25; 
SD=37.02), outpatient ER visits (mean=9.12; SD=15.35), inpatient 
visists (mean=4.72; SD=5.73), inpatient length of stay (mean=26.11; 
SD=35.76), and pharmacy visits (mean=3.24; SD=1.26). As expected, 
utilizations increased in positive correlation with the number of 
episodes (eg, patients with ≥3 episodes had four times more inpatient 
visits than patients with 2 episodes). (Figure 2A)
Evaluation of SCD-related costs found total costs were highest 
among patients who had ≥3 episodes, with a mean of US$58 950 
(SD=US$93 147). Across the 4 cohorts, the largest cost driver was 
inpatient costs; the ≥3 cohort had the highest mean inpatient costs 
of US$45 088 (SD=US$85 112), followed by pharmacy, outpatient 
hospital, and outpatient ER costs. As with utilizations, costs increased 
for patients with a higher number of VOC episodes (eg, patients with 
≥3 episodes incurred 4–5 times the total costs and inpatient costs of the 
2-episode cohort). (Figure 2B)
In addition, the frequency distribution of SCD-related health 
care costs for patients with FFS coverage was examined. Patients with 
total cost of US$0 were excluded because the actual cost might not 
have been captured. The mean total cost for patients with 0 pain 
crisis to ≥3 crisis ranged from US$5516 to US$62 577 during the
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12 months of follow-up. Also, the frequency distribution for the total 
SCD-related health care costs also showed that patients with ≥3 crisis 
incurred a maximum total health care cost of US$1 125 371. (Figure 3)
Costs Per VOC Episode by Different Places of Service
Among the 4247 total adult SCD patients with FFS Medicaid, 2316 
(50.9%) had ≥1 VOC episode after the index date. A total of 40 772 
VOC episodes were identified in the following settings (in hierarchical 
order): 15 395 from inpatient, 14 779 from ER, 7420 from outpatient, 
2365 from office, and 813 from other settings. The mean duration of 
each episode was 5.5 days (SD=11). 
The mean total medical cost per VOC episode was US$4861 
(SD=US$14 296). The mean costs per VOC episode varied widely across 
different settings, with inpatient VOCs incurring by far the highest 
per-episode cost (mean=US$11 398, SD=US$21 358), followed by ER 
(US$1072 [SD=US$3458]), outpatient (US$695 [SD=US$2437]), 
and office settings (US$306 [SD=US$1480]). (Figure 4)
Figure 2a. SCD-related HCRU Stratified by Number of Pain Episodes in 1 Year
ER: emergency department; LOS: length of stay
Figure 2b. SCD-related Medical Costs Stratified by Number of Pain Episodes in 1 Year
ER: emergency department; LOS: length of stay
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Figure 3. Frequency Distribution for Total Healthcare Cost Among FFS SCD Patients Stratified by Number of Crisis Episodes.
Figure 4. Healthcare Costs per VOC Episode by Settings
ER: emergency room
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DISCUSSION
This study explored the medical expenditures of adult SCD patients, 
detailing the breakdown of utilizations and costs not only by number 
of VOC episodes but also per-episode, stratified by setting. The results 
revealed the biggest cost drivers to be inpatient vistis and pharmacy, 
and shed more light on the economic burden of the disease. Although 
other studies have explored the economic burden of SCD, most were 
conducted at the individual state level and relevant only to specific 
treatments,23-25 or focused mainly on outcomes in the pediatric 
population.10,26,27 This study adds real-world evidence with more 
granular insight into clinical profiles and economic outcomes among 
the adult SCD population at the national level.
Previous studies indicate that VOC frequency, more so than 
pain duration or pain severity, is associated with increased utilization 
of health services,28 and the economic burden of SCD has been 
recognized for decades. Multiple studies have reported substantial 
medical expenditures among various SCD populations, with the 
average annual adult SCD-related costs ranging from US$11 508–
US$21 792 in 2005,29-31  which is consistent with this study’s finding 
of US$20 206.
In addition, the present study showed that VOC episodes were 
the primary reason for the high medical utilizations and costs among 
the study population, based on the findings on the ratio of HCRU and 
costs, stratified by different number of VOC episodes. As expected, the 
study showed that patients with the highest VOC frequency (the ≥3 
episode cohort) incurred the highest health care costs. They accounted 
for 26% of the total sample, indicating that a large group of adult 
SCD patients were suffering from high-frequency VOC episodes, and 
this complication was inflating overall costs for the SCD population 
at large.
Hence, this study confirmed a correlation between episode 
frequency and HCRU and costs (the ≥3 episode cohort incurred 4–5 
times more total SCD-related medical costs and inpatient costs than 
the 2 episode cohort, for instance). This could reflect increases in 
episode severity requiring more resources, which was further suggested 
by the per-episode cost findings, as inpatient VOC episodes had high 
mean costs. Moreover, the costs per VOC episode included both VOC-
related costs and all other medical costs incurred by patients with VOC 
during the episode period, which more precisely reflects the real-world 
medical costs associated with VOCs. 
It is also important to note there are some barriers associated with 
acute VOC management. These include incomplete understanding of 
the underlying mechanism of vaso-occlusive pathophysiology, sparse 
access to SCD experts, lack of evidence-based treatment guidelines, 
and inconsistent adherence to health care provider indications.32 As 
VOC has a significant impact on patients and their families, the factors 
that contribute to VOC management should be re-evaluated and 
brought to the table for health care experts and decision makers to 
move toward more effective interventions. Also, medication like the 
newly approved crizanlizumab-tmca, which has shown efficacy in the 
reduction of VOC frequency in SCD patients, could be included in the 
management of SCD patients.33 This may help alleviate the burden of 
frequent VOCs in SCD patients. 
Further, an adjunct analysis examined the frequency distribution 
for the total SCD-related health care costs for FFS SCD patients. This 
analysis showed that patients with frequent crises could be associated 
with a huge economic burden of over US$1 million annually, as 
observed in some patients with more than 3 crises in a year. However, 
we cannot ascertain whether this high cost is mainly because of the 
high number of crises or the severe complications associated with the 
crises.
Limitations
While the study findings elucidate medical resource use and 
expenditures in this population, several limitations should be noted.
The study relied on descriptive statistical analysis of outcomes, 
which requires caution in drawing conclusions from cohort 
comparisons, as these results are trends without direct experimental 
testing, such as randomized controlled trials, and therefore imply only 
correlation, not causation. Moreover, claims data analysis has its own 
limitations. For example, the data and corresponding outcomes may 
be affected by administrative diagnosis coding errors, codes entered 
as rule-out criteria and not actual indications of disease presence, and 
deliberate misdiagnoses to justify claims for off-label prescriptions. 
Another limitation of the study is that in order to capture all SCD 
patients including those with low health care utilizations, patients with 
≥1 SCD diagnosis in any setting were identified as SCD patients; this 
might have inadvertently included some non-SCD patients due to 
coding discrepancies. Although this study shows a large proportion of 
patients had high VOC frequency, we believe there is underreporting of 
the true number of SCD patients who experienced VOC and frequency 
of the VOC because home-managed VOCs were not capturable in the 
dataset used for this study.
In addition, the dataset was from 2009–2013 and real-world 
clinical management of SCD may have changed since the end of the 
study period.
The dataset also presented another limitation specific to this study. 
As the target was HCRU and costs by facilities, only FFS patients were 
included in the analysis because costs for Managed Care enrollees are 
not recorded in the Medicaid MAX dataset. This reduced the sample 
size and limited the generalizability of the study outcomes to other 
populations. 
Notwithstanding these limitations, the study does lay the 
groundwork for further research that can put the analysis into more 
specific statistical models and examine how the economic outcomes 
are related to the reduction of VOC episodes, controlling for covariates 
such as patient demographics and clinical characteristics.
CONCLUSIONS
The study found VOC episodes are associated with significant economic 
burden among patients with SCD, as they led to higher frequencies 
of inpatient utilizations, which were the largest cost driver among 
the study population. Moreover, HCRU and costs were closely and 
positively associated with the number of VOC episodes. In particular, 
among patients who had 3 or more VOC episodes per year, those 
episodes accounted for over 90% of the SCD-related inpatient visits 
and costs. Thus, VOC frequency can be seen as a strong indicator for 
medical resource use and expenditures. These findings warrant future 
investigations among broader study populations with more sensitive 
analysis, and ultimately may help clinicians reduce VOCs and thereby 
mitigate the overall clinical and economic burden of SCD.
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